Special Issue

Skin Microbiome, a Long Story of Clinical Trials 2.0

Message from the Guest Editor

The scientific community continues to demonstrate the functional role of the human gut and skin microbiome as an inspirational source for future therapeutics. Despite the huge potential offered by these discoveries in providing health in the long run, future therapeutics are still limited by the challenges in obtaining relevant clinical outcomes. In recent years, skin has evolved as one of the most extensively described tissue regarding microbiome diversities linked to host physiology, age, environmental exposure, and diseases. Moreover, the role of the skin microbiome has been validated by clinical results with respect to atopic dermatitis, psoriasis, acne, and seborrheic dermatitis. This Special Issue gathers recent research and new results of the clinical evaluation of skin microbiome-based treatments. It will serve as guidance for scientists from the biopharmaceutical and academic community to investigate the causal role of the skin microbiota in disease and to create a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes.

Guest Editor

Dr. Lionel Breton

Former Scientific Director L'Oreal Research, Cilia Consulting CEO, IDEC Therapeutic (Telostim.com) CSO, Paris, France

Deadline for manuscript submissions

closed (31 July 2022)

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/106104

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/microorganisms

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/microorganisms

About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich
Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

MDPI